On June 1, 2016, the US FDA approved the first “liquid biopsy†method based on EGFR gene mutations to detect EGFR exon 19 deletion and exon 21 L858R substitution mutation in patients with non-small cell lung cancer (NSCLC). In February 2015, China's CFDA also updated the Tarceva drug specification for targeted drugs, encouraging the use of ctDNA fluids on the basis of unevaluable tumor specimens.
Related company stock trends
Physical biopsy. In addition, Jazz announced last week that the acquisition of Celator will indirectly drive the A-share medical sector. This week, the annual meeting of the American Society of Clinical Oncology (ASCO) is about to close. Therefore, Monita Health believes that the precision medical market is re-emerging and it is recommended to pay attention to relevant industries and individual stocks.
Report summary
Market Review: Nasdaq Biotech continues to rise and the domestic market is significantly warmer.
The Nasdaq Biotech Index rose 59.88 points, or 2.07%, for the third consecutive week and rose by more than 10%. The domestic Shanghai Composite Index (4.17%) rose sharply, and the GEM Composite Index (+6.53%) Market sentiment rebounded markedly, and the CSI Shenwan Pharmaceutical Index (4.96%) also had a good rise.
FDA approves first EGFR variant liquid assay
The FDA approved the first EGFR variant fluid assay, Roche's cobas EGFRMutation Test v2, for the detection of EGFR exon 19 deletion and exon 21 L858R mutation in patients with non-small cell lung cancer. The Cobas EGFR Mutation Test v1 kit, which was previously used for the detection of the same mutation in the paraffin-embedded tissue section, has been approved by the FDA and CFDA, and the v2 kit will be extended to the field of liquid biopsy.
Zhongyuan Concord terminates non-public offering of shares
After the "Weize Xixi" incident, after careful study, the company decided to terminate the non-public offering of shares and was reviewed and approved at the 52nd meeting of the 8th Board of Directors. The company will hold an investor briefing on June 6 and disclose the investor announcement at the same time as the stock resumption.
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bodybuildingoil.com